RT

RT is an investigational triple-agonist peptide that targets the GLP-1, GIP, and glucagon receptors. This unique mechanism has generated significant interest within the scientific community due to its potential effects on energy balance, metabolic function, glucose regulation, and body composition.

In clinical research, RT has demonstrated substantial reductions in body weight, with participants achieving up to 28.2% average weight loss over the course of treatment. Ongoing studies continue to evaluate its potential role in metabolic health and weight management.

Product Information

Ships from Canada for fast and reliable domestic fulfillment.

• Supplied as a lyophilized (freeze-dried) powder
• Requires reconstitution prior to use
• Does not arrive in liquid form
• Intended for laboratory research purposes only

Clinical Data Highlights:

• Weight Loss: Up to 24.2% body weight reduction in phase 2 trials, highest recorded among incretin-based therapies

• Glycemic Control: HbA1c reductions of 2.0–2.5% in type 2 diabetes patients

• Lipid Profile: Significant drops in triglycerides, LDL-C, and liver fat content

• Insulin Sensitivity: Improved HOMA-IR and fasting insulin levels

• Energy Expenditure: Increased basal metabolic rate and fat oxidation via glucagon receptor activation